MINI FUTURE LONG - ZEALAND PHARMA | Real-time Bid/Ask 03:51:20 28/05/2024 pm IST | ||
| 5.73 EUR / 5.78 EUR | +5.60% |
|
| Current month | -4.72% | ||
| 1 month | -3.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 5.48 | +0.55% |
| 27/24/27 | 5.45 | +6.24% |
| 24/24/24 | 5.13 | -4.65% |
| 23/24/23 | 5.38 | -2.00% |
| 22/24/22 | 5.49 | +2.81% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 12:24 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB26CB |
| ISIN | DE000MB26CB7 |
| Date issued | 10/01/2023 |
| Strike | 198 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.61 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.05 € |
| Spread % | 0.87% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
617
DKK
Average target price
785.6
DKK
Spread / Average Target
+27.32%
- Stock Market
- Certificates
- Certificat
